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Abstract
In this study we have made novel observations with regards to potentiation of the tumoricidal
activity of the oncolytic adenovirus, dl1520 (ONYX-015) in rat glioblastoma cell lines expressing
heat shock protein 72 (HSP72) due to permissive virus replication. ONYX-015 is a conditionally
replicating adenovirus that is deleted for the E1B 55 kDA gene product whose normal function is
to interact with cell-cycle regulatory proteins to permit virus replication. However, many murine
and rodent cell lines are not permissive for adenovirus replication. Previously, it has been reported
that the heat shock response is necessary for adenovirus replication and that induction of heat
shock proteins is mediated by E1 region gene products. Therefore, we hypothesized that HSP72
expression may allow for permissive replication of ONYX-015 in previously non-permissive cells.
Rat glioma cell lines 9L and RT2 were transfected with a plasmids expressing HSP72 or GFP. After
infection with ONYX-015, no tumoricidal activity is observed in GFP expressing cell lines despite
adequate transduction. In contrast, HSP72 transfected cells show cytopathic effects by 72 hours
and greater than 75% loss of viability by 96 hours. Burst assays show active virus replication in the
HSP72 expressing cell lines. Therefore, 9L-HSP72 and RT2-HSP72 are ideal models to evaluate the
efficacy of ONYX-015 in an immunocompetent rat model. Our study has implications for creating
rodent tumor models for pre-clinical studies with E1 region deleted conditionally replicating
adenovirus.
Background
Adenovirus vectors are commonly utilized in cancer gene
therapy experiments. They readily infect numerous tumor
cell types and are easily manipulated allowing for trans-
gene expression[1]. In an effort to improve selectivity of
these vectors for malignant cells, replication selective or
conditionally replicating adenoviruses were created[2].
With greater understanding in the molecular aspects of
adenovirus replication, these viruses were designed such
that replication was predicated on alterations in cell cycle
regulation, thus rendering only malignant cells suscepti-
ble. These adenovirus systems rely on virus replication as
a means of exerting tumoricidal effect. One of the first of
these conditionally replicating adenoviruses was dl1520
or ONYX-015[3]. It has been used extensively in cancer
gene therapy clinical trials[4,5]. This virus is deleted for
the E1B-55 kDA gene[6].
The E1 region genes of the common serotypes of adenovi-
rus optimize their own replication in target cells and inter-
act with many cell cycle associated gene products. The E1a
region genes promote transition of cells into S phase
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through their interaction with the retinoblastoma protein
(pRB)[7]. pRB in conjunction with p53 can inhibit transi-
tion of cells into the S-phase of the cell cycle. Binding of
E1a to pRB prevents association of pRB to the E2F tran-
scription factor resulting in activation of E2F[8]. E2F then
functions to transition cells into the S-phase of the cell
cycle which is conducive for optimal adenovirus replica-
tion. In wild type adenoviruses, the role of the E1B-55
kDa gene product is to neutralize p53[9,10]. p53 induc-
tion is thought to promote cell cycle arrest resulting in ter-
mination of the virus replicative lifecycle in that cell[11].
Thus it was hypothesized that deletion of the E1B-55 kDa
gene product would result in p53 induced termination of
virus replication in normal cells while being replication
permissive in malignant cells with abnormal p53 expres-
sion or regulation[9]. Early reports with ONYX-015 indi-
cated replication selectivity for tumor cells with abnormal
p53 functioning[12]. However, the exact mechanism of
replication selectivity has been brought to question with
subsequent reports of ONYX-015 replication independent
of p53[13] and researchers have looked at other factors
associated with adenovirus replication.
Various heat shock proteins have been shown to be neces-
sary for efficient adenovirus replication. The avian adeno-
virus CELO requires the induction of HSP70 and HSP40
for production of viral proteins[14]. CELO mutants lack-
ing the E1 region genes were replication incompetent in
A549 cells. However, heat shock protein induction or
expression allowed for permissive replication of these
mutants. Similarly in a number of human cell lines, both
heat shock and HSP72 expression enhanced the oncolytic
effect of E1 containing adenovirus but not for E1 deleted
adenovirus[15].
Adenovirus E1 region genes from serotype 5 and 12 have
previously been shown to induce HSP72 expression [16].
HSP72 is a molecular chaperone protein involved in the
repairing denatured proteins. Through this role, it can
inhibit apoptosis downstream of caspase activation but
prior to loss of mitochondrial membrane potential[17].
Stably transfected or E1 transformed cell lines show con-
stitutive expression of the inducible HSP72 [18]. HSP72
levels are correlated with cell-cycle with increases in
HSP72 during S-phase with a maximum level in the post-
S-phase period [19]. In 293 cells which are transformed
with the adenovirus E1 region gene, E1A mRNA accumu-
lated just prior to HSP72 expression suggesting that E1A is
responsible for the cell cycle regulation of HSP72 expres-
sion [18]. Additionally, HSP72 co-localizes with E1A gene
products in infected cells [20]. HSP72 is predominately
cytoplasmic but translocates to the nucleus following ade-
novirus infection. Double labelling experiments with E1A
and HSP72 in infected cells showed co-localization of
these molecules within the nucleoli and exhibited similar
reticular and punctuate nuclear staining patterns depend-
ing on cell cycle. HSP72 transport to the nucleus was E1A
and virus infection dependent. In 293 (E1 region trans-
formed) cells, HSP72 and E1A co-localization was not
observed until after infection with virus [20]. These data
suggest a physical complex is necessary between adenovi-
rus E1A, HSP72 and other adenovirus gene products
One of the difficulties with studying E1 adenovirus dele-
tion mutants is the lack of appropriate animal tumor
models which allow for permissive growth of these
viruses. Common animal tumor models for glioblastoma
are the cell lines 9L and RT2. Previously, it has been
shown that replication competent E1 deletion mutants
can transduce 9L cells and result in transgene expression
but there is a block against virus replication[21]. In this
study we addressed if HSP72 expression could allow for
permissive replication of the ONYX-015 adenovirus in
these rat glioblastoma cells.
Results
Transduction Efficiency
Prior to studying the efficacy of ONYX-015 to result in
tumor cell lysis, we determined the optimal dose neces-
sary for tissue transduction. Adenovirus infection effi-
ciency is predicated on the expression of adenovirus
surface receptors[22]. Using a recombinant adenovirus
expressing green fluorescent protein (GFP), we transduced
various glioma cell lines and analyzed them by fluores-
cence microscopy. Results are summarized in Table 1.
Both the rat cell lines, 9L and RT2 required a significantly
high dose of adenovirus to result in effective transduction.
In contrast, the human glioma cell lines, DBTRG and
NB4, require much less virus for efficient transduction.
Cytopathic Effect
The dramatic difference in tumoricidal effect between
HSP72 transfected and control tumor cells is best
observed by cytopathic effect. In Figure 1 we show the
affects of virus infection on RT2-GFP and RT2-HSP72 cells
96 hours after infection with ONYX-015. Non-infected
RT2-GFP and RT2-HSP72 cells showed normal glioma
histological features and growth characteristics (Figure 1,
panel A and B). The cells were infected when 50% conflu-
ent. At 96 hours, RT2-GFP cells infected at MOI of 100 or
300 showed little cytopathic effect and very little differ-
ence was ascertained in comparison to non-infected cells
(Figure 1, panel C and E). In contrast, the majority of RT2-
HSP72 cells were dead or dying (Figure 1, panel D and F).
The few remaining cells were larger in size with oval or
round morphology. These cells showed morphological
characteristics consistent with adenovirus replication as
observed in 293 cells. Similar results were obtained when
assessing 9L-HSP72 cells. In table 2 we show the time to
full CPE in the rat glioblastoma cell lines and a variety ofMolecular Cancer 2005, 4:12 http://www.molecular-cancer.com/content/4/1/12
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human controls. Given the differences in transduction
efficiency, the human cell lines were infected at a lower
multiplicity of infection. No CPE is detected in the 9L-GFP
and RT2-GFP cell lines. In contrast, 9L-HSP72 and RT2-
HSP72 show CPE in as little as 4 days comparable to
human glioblastoma cells when infected at an MOI of 10
and show CPE more rapidly than the human cell lines
despite a lesser transduction efficiency.
HSP72 Expression Augments ONYX-015 Toxicity
When HSP72-transfected cells were infected with a low
dose (MOI 100) of ONYX-015, there is no loss of cell via-
bility. However, comparison of cell numbers to GFP-
transfected cells or AD-GFP infected cells showed a dra-
matic cytostatic effect (Figure 2). 9L-GFP and 9L-HSP72
cells were transduced with either AD-GFP or ONYX-015.
There is no effect on cell proliferation over time of the 9L-
GFP cells infected with either AD-GFP or ONYX-015 (data
not presented). In contrast, the 9L-HSP72 cells show nor-
mal proliferation when infected with AD-GFP infected
cells and their cell numbers increase over time. However,
ONYX-015 infected 9L-HSP72 cells showed loss of prolif-
erative potential with very little increase in cell number
over time. After 72 hours, the AD-GFP infected cells
showed a decrease in proliferation but this is likely due to
overcrowding of cells in the tissue culture vessel and/or
the rapid utilization of consumable energy in the media.
When assessing for cell viability, 9L-GFP (figure 3) and
RT2-GFP (figure 4) cells exhibited minimal toxicity when
infected with ONYX-015. In contrast, both 9L-HSP72 and
RT2-HSP72 cell lines were more susceptible to ONYX-015
cell lysis. In both HSP72 transfected cell lines, loss of cell
viability began as early as 24 hours after infection. Both
9L-HSP72 and RT2-HSP72 show greater than 90% loss of
viability by 96 hours.
Burst Assays
The mechanism of cell death associated with replication
competent adenoviruses has been attributed to release of
virus from cells following virus replication. Having
observed cytopathic effects (figure 1) in association with
ONYX-015 infection of 9L-HSP72 and RT2-HSP72 cells,
we presumed the same mechanism applied. To confirm
this hypothesis we evaluated adenovirus replication in
GFP and HSP72 transfected tumor cells by burst assay. In
a normal burst assay, an increase in virus titer after 72
hours is indicative of virus replication. Tumor cells were
also infected with the replication incompetent virus (AD-
GFP) as a negative control and no significant virus
Table 1: Transduction efficiency of various CNS tumor cell lines by AD-GFP Numbers represent percentage of cells transduced with a 
recombinant adenovirus vector expressing green fluorescent protein (AD-GFP) at the stated multiplicity of infection (MOI). 
Transduction was determined by fluorescence microscopy of cells on a hemacytometer and is represented as % of total cells.
Multiplicity of Infection
Cell Line 0 1 10 100 300 500 1000
9L 0 0 1 27 54 63 74
RT2 0 1 8 41 68 81 93
DBTRG 0 69 100 100 - - -
NB4 0 74 100 100 - - -
Table 2: Time to Cytopathic Effect Cells grown in 96 well plates were infected with ONYX-015 at the stated multiplicity of infection 
per row of cells. Values represent days until 50% of wells in a row showed cytopathic effect.
Multiplicity of Infection
Cell Line 0 1 10 100 300
9 L - G F P 00000
9 L - H S P 7 2 00854
R T 2 - G F P 00000
R T 2 - H S P 7 200044
DBTRG 0 6 4 - -
N B 4 054--
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Cytopathic effect of ONYX-015 on GFP and HSP72 transfected glioma cells Figure 1
Cytopathic effect of ONYX-015 on GFP and HSP72 transfected glioma cells. Photographs (100× magnification) of 
RT2-GFP and RT2-HSP72 cells 96 hours after ONYX-015 infection at various dosages are represented. A – RT2-GFP cells 
mock infected with virus. B – RT2-HSP72 cells mock infected with virus. C – RT2-GFP cells infected at MOI of 100. D – RT2-
HSP72 cells infected at MOI of 100. E – RT2-GFP cells infected at MOI of 300. F – RT2-HSP72 cells infected at MOI of 300.Molecular Cancer 2005, 4:12 http://www.molecular-cancer.com/content/4/1/12
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replication was measured (data not presented). Since
HSP72 transfected cells were susceptible to ONYX-015
mediated cell death we expected an increase in virus titer
if the cell death was a result of permissive adenovirus rep-
lication. After infection of cells with ONYX-015, the 9L-
HSP72 and RT2-HSP72 cells showed an increase in virus
titer confirming virus replication (figure 5) in contrast to
9L-GFP and RT2-HSP72 transfected cells. There was a
direct correlation between virus titer and cell death. Virus
titer in both GFP transfected and HSP72 transfected cells
increased in proportion to cell death.
Discussion
ONYX-015 is a promising new cancer gene therapy vector
which exerts its tumoricidal effect by selective replication
in cancer cells[6]. Replication selectivity previously was
attributed to interactions of E1 gene products with p53[3].
Subsequent reports have shown that ONYX-015 replicates
in cells with wild-type p53 as efficiently as in cells with
mutant-p53[13]. Although the mechanism of cancer cell
selectivity is still under investigation, the various hypoth-
eses consistently involve cell-cycle regulatory proteins and
their interactions within apoptosis pathways. HSP72 is a
Cytostatic effect of ONYX-015 infection on HSP72 transfected 9L cells Figure 2
Cytostatic effect of ONYX-015 infection on HSP72 transfected 9L cells. 9L-HSP72 cells were transduced with either 
AD-GFP () or ONYX-015 (■ ) at a multiplicity of infection of 100. Cell numbers were determined over time (X-axis) by 
direct counting using a Coulter Counter. Values (Y-axis) represent log of cell number as a fraction of the initial cell number 
plated.
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potent regulator of apoptosis [23]. Also, there is evidence
that activation of the heat shock response by adenovirus
early region genes is necessary for virus replication[14].
Previously it has been shown that heat shock induced
HSP72 expression resulted in increased production of
adenovirus proteins[24]. Additionally, the E1A adenovi-
rus gene products necessary for virus genome replication
have previously been shown to co-localize with
HSP72[20].
To study the role of HSP72 in augmenting ONYX-015 rep-
lication, we chose two glioma cell lines with different der-
ivations. 9L is a chemically induced gliosarcoma while
RT2 is a virally transformed glioblastoma. Compared to
many human tumor cell lines, these cell lines show rela-
tive resistance to the cytotoxic affects of ONYX-015.
Resistance in part was secondary to low adenovirus trans-
duction efficiency. At the multiplicities of infection uti-
lized in this study, we never achieved 100% cell
transduction (table 1). In most cases, when less than 30%
of permissive HSP72-transfected cells were transduced,
tumor cell growth was rapid and outpaced ONYX-015
virus replication resulting in no discernable cytotoxic or
cytostatic effect after 1 week in culture (data not pre-
sented). Therefore, replicative adenovirus cytotoxicity is
likely a balance between virus transduction efficiency, rep-
lication efficiency and cell growth characteristics. HSP72
transfection had no bearing on cell doubling time of
9L Cell viability after ONYX-015 infection Figure 3
9L Cell viability after ONYX-015 infection. Cell viability (as % viable cells; y-axis) of 9L-GFP (■ ) and 9L-HSP72 (● ) cell 
lines after infection with ONYX-015 at a MOI of 300 over time (x-axis). There is statistical significance (p < 0.05) when com-
paring GFP and HSP72 transfected cell numbers by analysis of variance at the 72 and 96 hour time points.
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either 9L or RT2 cells (data not presented) RT2 cell-dou-
bling time is approximately 8 hours while 9L cell-dou-
bling time is approximately 14 hours. Both cell lines after
HSP72 transfection showed equal susceptibility to ONYX-
015. Further evidence for the balance between transduc-
tion efficiency, replication efficiency and cell doubling
time is evident in that ONYX-015 infection resulted in a
predominantly cytostatic affect resulting in decreased cell
division before evidence of cytotoxicity.
The most dramatic affect of the role HSP72 in promotion
of virus replication is evident in figure 1. At 96 hours, the
GFP transduced cells showed very little cytotoxic effect of
ONYX-015 infection. In contrast, there is a distinct cyto-
pathic effect at the same doses of ONYX-015 infection in
the HSP72 transduced cells. These cells were rendered sus-
ceptible to ONYX-015 toxicity. The mechanism of cell
death is related to increased virus replication. Significantly
more ONYX-015 was isolated from HSP72 transduced
cells than the GFP-transfected controls.
The E1a gene products of adenovirus are responsible for
activation of the HSP72 promoter and may affect HSP72
levels during the cell cycle[18]. Conversely, there is no evi-
dence that HSP72 interacts with adenovirus promoters to
stimulate viral transcription. There is evidence of HSP72
interactions with adenovirus structural proteins such as
hexon[25] and fiber[26]. Adenovirus assembly is known
RT2 Cell viability after ONYX-015 infection Figure 4
RT2 Cell viability after ONYX-015 infection. Cell viability (as % viable cells; y-axis) of RT2-GFP (■ ) and RT2-HSP72 (● ) 
cell lines after infection with ONYX-015 at a MOI of 300 over time (x-axis). There is statistical significance (p < 0.05) when 
comparing GFP and HSP72 transfected cell numbers by analysis of variance at the 72 and 96 hour time points.
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to be inefficient with only a small percentage of total
structural proteins eventually utilized in the production of
infectious virus [26].
In conclusion, our studies demonstrated that HSP72
expression in rodent glioma tumor cells potentiated
ONYX-015 replication and oncolysis of tumor cells. Fur-
ther studies on the role of HSP72 in tumor types with
wild-type and mutant p53 tumor suppressor genes is war-
ranted to understand the molecular interactions of this
chaperone protein in promoting virus replication. Addi-
tionally, addressing the role of HSP72 as an inhibitor of
apoptosis in virus replication would further help
characterize the interaction of cell-cycle regulatory path-
ways with virus replication. Furthermore, we intend to
evaluate the role of HSP72 associated permissive replica-
tion in other animal cell lines to establish animal models
for the study of ONYX-015 and similar replication compe-
tent adenoviruses.
Conclusion
For clinical applicability, these findings have a number of
implications. Currently, clinical trials are ongoing with
ONYX-015. Due to the previous association of ONYX-015
replication with p53 status, the current tumor types cho-
sen for clinical trials are those exhibiting abnormal p53
Burst assays Figure 5
Burst assays. Burst ratio is given as the virus titer at 72 hours compared to 4 hours of various cell lines (x-axis) infected while 
50% confluent with ONYX-015 at MOI of 100. Results are representative of a typical experiment of at least three performed. 
(*) represents statistical significance (p < 0.05) by Student's t-test between 9L-HSP72 and 9L-GFP. (**) represents statistical sig-
nificance (p < 0.05) by Student's t-test between RT2-HSP72 and RT2-GFP.
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expression in a majority of cells. Our study indicates, that
tumor types with high HSP72 may also be viable candi-
dates to evaluate ONYX-015 efficacy, as they are likely to
demonstrate enhanced susceptibility to this replication
competent virus. As HSP72 expression in tumors is asso-
ciated with a more aggressive tumor phenotype, ONYX-
015 may be ideal as adjunctive therapy for advanced dis-
ease. Additionally, one of the greatest limitations to aden-
ovirus gene therapy is patient safety at high doses of
adenovirus administration. Since, HSP72 expression
resulted in oncolysis at much lower MOIs, a lower dose of
virus administered to a HSP72 positive tumor may have
the same benefit as a higher dose, allowing one to use
lower doses to achieve the same effect. In addition, for
some tumor types such as breast cancer, hyperthermia has
been shown to significantly improve response rates[27].
HSP72 is readily induced with hyperthermia. Therefore,
HSP72 induction by hyperthermia may also serve as an
effective strategy to augment ONYX-015 oncolytic activ-
ity. We are currently in the process of studying this
hypothesis. Lastly, the role of HSP72 in cell cycle regula-
tion suggests alternate pathways for the mechanism of
E1b deleted adenovirus replication in tumorigenic cells.
HSP72 overexpression in non-transformed fibroblasts did
not result in ONYX-015 oncolysis (data not presented).
Understanding the molecular interactions of adenovirus
proteins with molecular chaperones would help deter-
mine cell selectivity to replication competent adenovi-
ruses influencing the design of more potent viruses.
Methods
Cell Lines
9L and RT2 cells are rat glioma cell lines with different der-
ivations. 9L cells are chemically induced gliosarcoma
cells[28] while RT2 are virally transformed and have
glioblastoma histology[29]. These cell lines were obtained
from Dr. Martin Graf (Medical College of Virginia, Rich-
mond, VA). Cells were kept at 37°C, 5% CO2 and 95%
humidity in Dulbecco's modified eagle medium (Cellgro,
Herndon, VA) supplemented with 10% (v/v) heat inacti-
vated fetal bovine serum (BioWhittaker, Walkersville,
MD), 2 mM L-glutamine and 100 units/ml Penicillin and
1000 ug/ml Streptomycin (Invitrogen). 9L and RT2 cells
were transfected with the plasmids pEGFP-N2 (Clontech)
or pHSP72 using Lipofectamine (Invitrogen) according to
the manufacturers protocol followed by selection in 0.2
mg/ml G418 (Invitrogen). 293 cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA;
CRL-1573) were used for virus propagation and
purification.
Plasmid Creation
pHSP72 was created by ligation of the DNA Polymerase
blunt ended 2.3 KB Bam H1-Hind III fragment from plas-
mid pH2.3 (ATCC) into the blunt ended Xho1-XbaIA vec-
tor pEGFP-N2.
Adenovirus
Creation of ONYX-015 has previously been described[6].
The virus was propagated on 293 cells and purified by
cesium chloride gradient followed by dialysis. Virus was
stored at -80°C until use. Titer was determined by tissue
culture infectious dose-50 method (TCID-50). Briefly,
293 cells were plated at 104 cells/well in 96 well flat-bot-
tomed tissue culture plates. Virus titer from combined
supernatant and freeze-thawed cell lysate was determined
by serial 10-fold dilution into different rows of the titer
plate. After 10 days, wells were scored for cytopathic
effect. The titer was calculated using the formula T =
101+d(S-0.5) where d is the Log 10 of the dilution and S is
the sum of the ratios of positive wells in each row. A more
lengthy description of this method is provided in the ade-
novirus application manual at http://www.qbio
gene.com.
Adenovirus Infection
Cells were infected when 50% confluent with the dose of
adenovirus given in the appropriate table. The infection
was performed in serum free DMEM media for 90 min-
utes at 37°C and 5% CO2. Cells were subsequently
washed with phosphate buffered saline and then cultured
in complete medium.
Cell Viability Determination
Cell viability was determined by the standard Trypan-blue
exclusion test. Cells were washed with PBS and then lifted
from tissue culture plates with Trypsin-EDTA solution
(Invitrogen). Cells were stained with 0.2% Trypan blue
solution for 5 minutes and then counted on a
hemacytometer.
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